# JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

> **NCT07497074** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 78 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** JSKN033
- **DRUG:** Platinum
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07497074
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-10
- **Final completion:** 2028-06
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497074, "JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07497074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*